Call for Entries: Join the Timmerman Traverse for Damon Runyon Cancer Research
Are you ready for a bucket list adventure?
Join me and a team of biotech executives and investors on the Timmerman Traverse for Damon Runyon Cancer Research Foundation.
It’s a trek to Everest Base Camp (17,600 feet) in April 2025.
Who’s on the Team?
- Luke Timmerman, founder & editor, Timmerman Report (team captain)
- Soufiane Aboulhouda, co-founder and CEO, Nucleate
- Tamar Kavlashvili, Timmerman Traverse Fellow, Damon Runyon Cancer Research Foundation; research fellow, Memorial Sloan Kettering Cancer Center
- Kamal Puri, chief scientific officer, OncoResponse
- Meg Alexander, president and chief operating officer, Ovid Therapeutics
- Victoria “Tori” Fort, senior vice president of strategy and corporate affairs, Frontier Medicines
- Andrew Warren, senior director, CSO Partner team, Curie Bio
- George Eastwood, interim executive director, Emily Whitehead Foundation
- Martin Strebl-Bantillo, principal, Lumanity
- Susan Whitehead, principal, BioSavvy Advisors
What Will I Do?
- Raise awareness for cancer research
- Raise money to propel the careers of young scientists
- Form meaningful relationships
- Have fun
When is the Trip? Apr. 11-27, 2025.
L to R: Henry Kilgore, Luke Timmerman, and Will Chen on Kilimanjaro, Feb. 2024. Henry and Will are Damon Runyon Fellows at the Whitehead Institute and the University of Washington, respectively.
Where: Everest Base Camp trek in Nepal. It’s one of the superb high-altitude treks in the world.
Why Damon Runyon? It supports brilliant young cancer researchers across the US.
Damon Runyon has a keen eye for talent. In its more than 75-year history, its grant recipients have gone on to win:
- 13 Nobel Prizes
- 7 National Medals of Science
- 104 elected members of the National Academy of Sciences
Damon Runyon grants have catalyzed many major advances in science, including:
- The first chemotherapies to cure a solid tumor.
- The first targeted ALK inhibitor for lung cancer.
- The first demonstration that CRISPR could edit genes in mammalian cells.
- Cancer immunotherapy with checkpoint inhibitors and CAR-T cell therapy as far back as the mid-2000s, long before these treatments became mainstream.
How Will I Do It? You will work hard to prepare physically and mentally.
Ten spots are taken.
Seven spots left.
If you work at a company committed to cancer R&D, this is a rare opportunity for your company to sponsor you and a network of brilliant young scientists.
Are you ready for this experience of a lifetime?
Ask me for more information by Oct. 18, 2024.
luke@timmermanreport.com.
